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Abstract 
‘Right To Try’ (RTT) laws originated in the USA to allow terminally ill patients to 
request access to early stage experimental medical products directly from the producer, 
removing the oversight and approval of the Food and Drug Administration. These laws 
have received significant media attention and almost equally unanimous criticism by the 
bioethics, clinical and scientific communities. They touch indeed on complex issues such 
as the conflict between individual and public interest, and the public understanding of 
medical research and its regulation. The increased awareness around RTT laws means 
that healthcare providers directly involved in the management of patients with life-
threatening conditions such as cancer, infective, or neurologic conditions will deal more 
frequently with patients’ requests of access to experimental medical products.  
This paper aims to assess the ethical plausibility of the RTT laws, and to suggest some 
possible ethical tools and considerations to address the main issues they touch. 
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1. Introduction  
The Right to Try (RTT) laws originated in USA in 2014 at the Goldwater Institute, a 
conservative libertarian public policy think-tank in Phoenix, Arizona (1). They allow 
terminally ill patients (patients in an advanced stage of a disease with an unfavorable 
prognosis and no known cure)   to request access to early stage experimental (with as-
yet-unknown efficacy and adverse effects) medical products (drugs, treatments, 
biologics, and other medical devices), directly from the producer, removing the oversight 
and approval of the Food and Drug Administration (FDA). Although based on the 
Goldwater Institute’s blueprint, they vary between different states. The main RTT laws 
requirements (2) are: 
 The patient has a diagnosis of a terminal disease (which in some states includes 
permanent coma) and no other treatment options are available. 
 The experimental product has passed Phase 1 safety testing and is at least in early 
Phase 2 safety and efficacy testing. 
 The patient’s healthcare provider (HCP) recommends the experimental medical 
product. 
 The patient, or a designated guardian, has given informed consent to take this 
product  
The HCPs are expected to give patients a description of the best and worst possible 
outcomes using an experimental treatment. However, the RTT laws absolve HCPs and 
producers (the pharmaceutical or biomedical company or manufacturer developing the 
product) from legal liability from any harm the experimental medical product can cause 
to patients. RTT laws are underpinned by the presumption of patients’ capacity to weigh 
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the risk and benefits and make informed medical decisions based on the information 
provided by their HCPs, and on their own values and desired outcomes. 
The first RTT law was passed in Colorado in 2014, and currently (November 2017) there 
are RTT laws in place in 38 states4. RTT bills have been introduced by both Republicans 
and Democrats and they have passed with unanimous support. These laws have proved 
very popular and have received significant media attention. In contrast, they have also 
received almost equally unanimous criticism by experts in the bioethics, law, clinical and 
scientific communities (3).  
1.1. Background: FDA Expanded Access 
Before entering the heart of the controversies, some background information is needed to 
understand the context in which RTT laws have emerged. When available treatments are 
ineffective, some patients with serious or terminal illnesses may wish to try experimental 
medical products, in the hope of receiving therapeutic benefit. The standard way to 
access such experimental products is by participating in a randomised control trial 
(RCT). As known, new medical products are not available to the public until they have 
been tested in Phase 3 of clinical trials; shown evidence of safety and efficacy; and 
gained approval from the FDA. This testing and approval process can take up to 10-15 
years. RCTs also require specific eligibility criteria that may preclude certain patients 
from participation, and these criteria often exclude terminally ill patients because they are 
more likely to develop adverse outcomes, risking both their lives and to jeopardise the 
RCT. Currently RCT access is also limited by patient geographical location, with rural 
areas particularly penalised. Therefore, terminally ill patients who do not qualify for or 
do not have access to a RCT may die waiting for a medical product to be approved and 
accessible. Moreover, terminally ill patients who can access RCTs, may not wish to risk 
to take the 50% chance of being assigned to a control group (who often receives a 
placebo or an already approved treatment, which would be ineffective for such patients) 
and therefore not obtain timely access to the experimental medical product they seek.  
These are among the main factors that have led some patients to seek experimental 
medical products on their own, also illegally from black or ‘grey’ markets (from other 
patients who sell their pills or share the ones they got in trials) (4). Since the 1970s, the 
                                                          
4 http://righttotry.org/in-your-state/  
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American patients have also legally pressured the FDA to expand access to experimental 
medical products. Under current FDA regulations, patients with serious or life-
threatening conditions can apply for Expanded Access (EA) to experimental treatments 
outside of a clinical trial and before the experimental medical product has been approved 
by the FDA5. This requires approval by both the FDA and by an independent Institutional 
Review Board (IRB) at the hospital or institution where the treatment will be 
administered. The objective of the EA programme is to balance speed and safety of 
access for the requesting patient, without interfering with the conduct or completion of 
the RCT (5). Some important measures help to achieve this objective:   
 The IRB acts as an independent third party whose tasks include reviewing 
research protocols; assessing the risks and benefits to safeguard patients; review 
consent forms, in particular the language and terminology used, to help ensuring 
that consent is informed and voluntary.   
 Before the FDA considers a request for EA the producer must agree to provide 
access to the product outside a RCT. The FDA can act as mediator between the 
patient and the producer, but has no authority to override a producer’s decision to 
not provide access.  
 Once access is given, the HCPs have to report follow-up clinical data about the 
patient  to the FDA (6). 
EA is normally granted for experimental medical products in Phase 2 or 3 in 
circumstances where there are no alternative therapies and the patients are ineligible or 
unable to participate in a RCT. It is important to highlight that EA also allows patients 
with immediate life-threatening conditions to apply for access to experimental medical 
products that have passed Phase 1 of RCT (7) – the same threshold of the RTT laws. 
However, unlike the RTT laws, the FDA always requires data suggesting the medical 
product is safe enough to give to patients. 
In recent years, the FDA has approved more than 99% of EA requests it received and has 
speeded up the approval process (8). The current FDA EA form normally takes 45 
minutes for HCPs to complete, and the FDA can answer emergency requests for EA in 
24 hours (8, 9). 
                                                          
5 We are briefly recalling only the American case, where the RTT laws have been implemented. The 
regulation, and terminology, for what is here called ‘expanded access’ varies from country to country. 
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To conclude this bird’s-eye view background, it is also important to point out that FDA 
EA and RTT laws are only a part of a broader set of diverse efforts to make medical 
products available before the completion of RCT (still considered the gold standard to 
assess the safety and efficacy of medical products), and/or to design different, faster 
methods. For example, surrogate endpoints, biomarkers or intermediate end points are 
increasingly used to substitute RCT and predict patient relevant outcomes (10). In 2014, 
the same year of the first RTT laws, in the context of the Ebola outbreak in West Africa, 
the World Health Organization declared that it is ethical to offer experimental 
interventions, provided that certain conditions are met (11). The Wellcome Trust (UK) 
has drafted guidelines to fast-track trials in humanitarian emergencies (12). The USA 
21st Century Cures Act (21CAA) developed in 2016 encourages the FDA to consider 
new evidentiary standards in the development and approval of new medical products, 
including data from Electronic Health Records (EHR). 
1.2 Relevance of discussing RTT laws 
Although RTT laws have emerged in the USA, the difficult issues they touch upon, and 
the complex area of end of life care in which they are situated, are relevant to other 
countries (13).  Such issues include: the balance of therapeutic beneficence between 
medical research centred on the public and clinical practice centred on the individual 
patient; the potential conflict between individual medical autonomy and the interest of 
public health and medical research; the public understanding of (and trust in) the process 
and regulation of medical research. These issues are not only of interest to clinical, 
medical scientists and other experts from different disciplines such as clinical lawyers, 
health regulators, social scientists, and bioethicists. The increased awareness around RTT 
laws – also ignited by a recent popular Hollywood movie ‘Dallas Buyers’ Club’, and by 
other stories of individuals who have attempted to obtain experimental treatments – 
means that it is likely that HCPs will deal more frequently with patients’ requests for 
access to experimental medical products. This will particularly be the case for HCPs 
directly involved in the management of patients with life-threatening conditions such as 
cancer, infective, or neurological conditions.    
1.3 Aims and outline of the paper  
We aim to provide a set of ethical tools and considerations that may help to address the 
main issues touched by the RTT laws and their critics. 
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In order to illustrate the key controversies of the RTT debate, we begin by reviewing the 
main arguments in favour (section 3) and against (section 4) RTT laws. RTT advocates 
claim that the laws support individual autonomy by removing unnecessary and time 
consuming ‘regulatory walls’ between terminally ill patients and the experimental 
products which may have some therapeutic benefit. Critics have expressed concerns 
about the real efficacy of these laws; the nature of the ‘right’ they confer to patients, and 
how they may contribute to health inequalities. They are also concerned about the 
negative consequences that unregulated access to experimental medical products may 
have for the patient requesting access, end of life care, the sustainability of medical 
research and clinical trials, and for public health.  In line with some literature (14), we 
acknowledge that RTT laws are situated within an important debate about how to 
improve terminally ill patients’ quality of life and decisions, but we argue that they do 
not provide an effective means to achieve this objective.   
The issues touched by the RTT debate are very complex and blend clinical, research, and 
social challenges. To tackle this complexity – and to address most of the concerns of 
RTT advocates and its critics – we outline in section 5, a multi-pronged approach.  
First, we suggest two complementary ethical tools to improve end of life decision making 
(promoting autonomy and quality of life for terminally ill patients, also beyond the 
problem of access to experimental treatments). These are models of consent based on 
trust, and an ethical counselling framework aimed at both patients and HCPs.  
We are also cognisant of the structural and social complexity of the processes and 
regulation of medical research, which is intensified by a ‘communication gap’ between 
experts and the public. Therefore, we suggest stakeholder engagement to inform the 
design and regulation of clinical research, considering the perspectives of the 
stakeholders; and more, more balanced, communication and education campaigns to 
foster constructive stakeholder engagement. Finally, we press that stakeholder 
engagement and any participatory endeavours should promote changes in RTT, or 
develop other programmes, that do not increase economic unfairness and inequality, 
unlike the current version of RTT laws.  
We searched the literature on RTT in three databases: PubMed, Web of Science and 
Google Scholar. We looked for publications with the key term ‘right to try’ in the title 
and/or abstract. Inclusion criteria for articles were English-language commentaries, 
reviews, and papers. We also searched through relevant journals separately to ensure we 
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had not omitted any relevant literature, and we found additional literature through 
citation tracking and snowballing. To complement our search, we explored some relevant 
grey literature including: blogs, online articles, reports, and university dissertations. 
The vast majority of the academic literature identified discuss RTT issues focusing on the 
USA, with some exceptions of papers which adopt a global public health perspective 
(15), analyse both UK and USA (13), and USA and Europe (16). Most articles address 
RTT from clinical practice (mostly oncology), medical research, legal and ethical angles, 
and one from psychiatry (17). 
Most papers tend to be either strongly critical of the RTT laws’ ethical, clinical and legal 
validity – some arguing for their dismissal (18); other deploying more moderate 
arguments still based on questioning the value of RTT laws, but recognising their intent 
and the importance of improving  regulation and access to experimental medical 
products, and of addressing the communication gap between experts, who oppose the 
laws, and the public (19). We managed to find only one paper in the scientific literature 
which endorsed RTT laws (20). Therefore the arguments in favour of the RTT laws 
presented in the section 3 below are principally extracted from the Goldwater Model 
legislation (21), the RTT webpage (http://righttotry.org/about-right-to-try/),  grey 
literature,  and  from the critical papers.  
3. The main arguments in favour of RTT laws 
The justifications for the RTT laws touch on the ethical principles of autonomy, 
beneficence, and justice, and so the main arguments used by their proponents can be 
summarised in the points below. 
3.1. RTT removes regulatory walls  
RTT laws are underpinned by a strong neoliberal framework. Central to these laws is 
patients’ right to life and to choose (with the involvement of HCPs) any experimental 
medical products that might prolong their lives without the mediation of 
governmental/regulatory bodies such as the FDA. Despite the efforts made by FDA to 
ease and speed the process of EA (see section 1.1), for RTT advocates EA remains an 
unnecessary and burdensome bureaucratic barrier that can delay access to experimental 
medical products.  RTT is also a play on ‘right to die’ i.e. terminally ill patients’ right to 
request lethal prescriptions. Some proponents of the RTT claim that it is inconsistent that 
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in some US states and other countries a patient has the right to take a lethal drug – by 
definition, with 100% probability of being unsafe – but does not have the right to try an 
experimental treatment with less than 100% probability of being unsafe and ineffective. 
Thus, these proponents claim that the RTT is embedded in the right to die (20). They see 
the right to die and right to life as two fundamental expressions of individual autonomy. 
3.2. RTT laws allow a timely access to experimental outcomes 
RTT proponents claim that medical products which have passed Phase 1 of clinical trials 
are already safe enough for patient consumption, or at least safe enough to give some 
hope to terminally ill patients. They often depict the FDA’s concern to ensure sufficient 
levels of safety and efficacy of the experimental medical products as mask that delays or 
prevents terminally ill patients from doing all they can to try to prolong their life. RTT 
advocates claim that applications for EA through FDA are time consuming for both 
HCPs and patients, placing an unnecessary burden on vulnerable terminally ill patients 
who have limited life expectancy (and are therefore pressured for time).  
3.3. RTT laws reduce inequalities  
RTT advocates claim that the laws rebalance access to the therapeutic benefit of 
experimental medical product in favour of terminally ill patients who tend not to be 
eligible to RCT, and in other circumstances e.g. if the medical products not approved by 
FDA are available in other countries. In this case not all patients willing to try these 
experimental products have the ability to travel/ move to these countries.  
3.4. RTT laws improve patient-HCPs communication and decision making  
For RTT proponents the laws enable patients to discuss with HCPs more therapeutic 
options. The so called ‘out of options talk’ in oncology (and other end of life care 
situations) is difficult for both patient and HCPs. RTT would postpone or avoid such 
difficult conversations offering instead more options and hopes to terminally ill patients.  
4. The main arguments against RTT laws 
The ethical principles of autonomy, benefice and justice are also key to the critics of the 
RTT laws. Nevertheless, critics tend to highlight two important weaknesses in these 
laws: an insufficient consideration of the tenuous nature of the development of new 
medical products, and an insufficient consideration of individual and public interests. The 
main arguments against RTT laws are summarised below.    
AC
CE
PT
ED
MA
NU
SC
RI
PT
9 
 
4.1. Formal vs substantial right   
RTT laws suggest that experimental medical products will be easily available to patients 
who request them (or more easily than FDA’s EA). However, the rights they confer to 
patients are only formal, and not substantial. The laws prevent the FDA from interfering 
with access to experimental products in the case of eligible patients, but they do not 
impose a positive duty on the manufacturer to make their products available (19). Thus, 
the decision about access rests on the company, and many companies are not inclined to 
grant access due to several factors, including:  
 Pre-approval access requires considerable effort (organisational, logistical and 
financial) and would limit the availability of the experimental product for the 
clinical trial, which is their higher priority. 
 Pre-approval access may slow the RCT and the final approval, harm the clinical 
trial, and even jeopardize the chances of approval. 
 If a terminally ill patients develops adverse effects, this may generate bad 
publicity possibly affecting the eventual profitability of the drug, and in the worst 
case the survival of the company (22). 
The fact that RTT laws absolve producers from legal liability from any harm the 
experimental medical product can cause on patients may help, but does not address the 
above concerns. On the other hand, it is worth recalling that under FDA EA, companies 
must first agree to provide the experimental product to the patient. Although the FDA 
cannot oblige the company to make the experimental product available outside RCT, the 
FDA often works with the company to avail the medical product to the patient (9) – 
contributing therefore toward a more substantial form of right to patients than RTT laws.  
 Therefore, the RTT laws can create an expectation or illusion of access. Contrary 
to the RTT laws’ idea of the FDA being a regulatory wall, the real gatekeeper for access 
to experimental products can be the manufacturer.  Obtaining the drugs from the 
producer is often more difficult than getting EA approved by the FDA (18).  
Some critics have also questioned whether RTT laws would even confer a formal right to 
patients. In the current federal law, the FDA regulatory apparatus is constitutional, and 
this would pre-empt RTT state laws, which aims to bypass the FDA (23, 24).  Moreover, 
while some proponents of RTT laws may still expect states independence from federal 
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FDA regulation of experimental medical products on a patient-by-patient level (14), it is 
unlikely that such independence would be kept in a public health emergency (e.g. a 
disease outbreak) which may require a multi-state coordination of the procurement and 
distribution of a large quantities of experimental medical products (15).  
From this perspective RTT laws appear to be a largely symbolic attack to the 
governmental authority of the FDA, masked by a libertarian ethos of conferring more 
rights to patients, but without any positive measures to guarantee these rights and 
autonomy.   
4.2. Inequalities  
Even if the company decides to grant access to the experimental product they are 
developing, there is another important consequence of the formal nature of right 
conferred by RTT laws.  If the company makes the product available, it can decide to 
charge the patient, and health insurers may not reimburse such costs. RTT laws do not 
provide financial support to patients seeking access (although there are some exceptions, 
e.g. Utah established a private foundation to address this concern; Texas RTT laws 
require the pre-approval medical product to be provided for free (25)).   
Patients may be personally responsible for paying for the experimental agent. Therefore 
RTT laws may reinforce pre-existing inequities: patients with financial means (who may 
also have more time, resources and educational skills needed to navigate a challenging 
healthcare system) are more likely to have greater access to these experimental 
treatments (26). They may also divert HCPs’ time, attention and resources from patients 
who are more burdened by disease personally or in their family, living in poverty, less 
articulate or less educated, have cognitive impairment. This would contribute to an 
inequality whereby less needy patients would receive more attention from HCPs than 
those who have more needs, as per Tudor Hart’s Inverse Care Law (27).   
It is also important to highlight that RTT laws present significant inconsistencies across 
states on what constitutes ‘terminally ill’, and these inconsistencies create both confusion 
and increase inequalities. For example RTT laws provide no directions for HCPs and 
patients in the case of a patient living in a state but receiving cures from an hospital in a 
different state with different definition of ‘terminally illness’ or other variations of RTT 
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laws when it comes to insurance or financial coverage for the experimental medical 
product.   
Another form of inequality stems from the RTT use of terminal diseases as eligibility 
criteria. These criteria exclude patients with serious but not life-threatening conditions 
e.g. those with degenerative diseases, untreatable depression, and chronic conditions.  
Eligibility criteria for EA are broader (“serious or immediately life-threatening disease or 
condition”6) and also include patients with serious conditions.  
4.3 Speed vs safety  
Many critics have expressed concerns that the RTT laws prioritise speed and downplay 
safety. The laws minimise the risk of taking experimental medical products, potentially 
exposing terminally ill patients to unnecessary harm.  Many experimental products that 
complete Phase 1 trials fail to receive FDA approval because in later phases of the trial 
they are found to have serious side effects (or to be ineffective). Notably, potential 
adverse events of experimental products are normally not known up to and including 
Phase 3 of RCTs. It is not surprising that a 2014 study shows that approximately only one 
in ten experimental medical products makes it through the FDA process and its approval 
for clinical use (28). Thus, the harm caused by experimental treatments accessed through 
RTT can often exceed the potential benefit (9). Advocates of RTT laws appear to 
overestimate the benefit that might be obtained by a new and still experimental treatment.  
Moreover they ignore the tenuous nature of the development of medical products .  
Other ways in which RTT laws can threaten patient safety have also been highlighted. 
Most versions of RTT laws do not establish a threshold of qualification for the HCP 
diagnosing the terminal illness in the patients or the HCPs/researcher recommending the 
experimental medical product. This may negatively affect the diagnosis of patients’ 
conditions, the prognosis and the assessment of the risk and benefits of the experimental 
medical product. It may also expose terminally ill patients to ‘experimental cures’ which 
are not validated by scientific evidence (18).  
 
Moreover, these laws may take health benefits away from patients. In some states, 
                                                          
6 https://www.fda.gov/ForPatients/Other/ExpandedAccess/ucm20041768.htm  
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patients who use an experimental treatment may lose their right to hospice care, home 
health care, or insurance (29, 30).  
Arguably this ‘speed over safety’ issue reveals a contradiction in RTT laws. The laws 
appear to trust (or rely on) medical research to the extent that even its early stage 
experimental products are worth trying as they may be beneficial – but at the same time 
they do not trust the process used by medical research to test and develop such products. 
4.4. Individual vs public interest  
RTT laws raise ethical and regulatory questions about the equitable balance of individual 
and public interests. A fundamental question is whether and to what extent producers and 
research teams should re-direct experimental products and resources from RCTs to 
individual patients, and how this should be financed. Granting access to individual 
patients for experimental medical products may compromise the set up and completion of 
the RCT that would ultimately benefit a larger number of people. 
As discussed above, RTT may facilitate the use of experimental medical products that are 
contraindicated especially to more vulnerable patients. Even if patients with life-
threatening conditions may be willing to assume the risk of taking experimental and 
potentially contraindicated medications, the adverse outcomes they may develop (adverse 
outcomes are more likely in terminally ill patients compared to eligible RCT participants) 
could delay or even derail the eventual approval of the product. For example, they may 
discourage companies from proceeding with the RCT or they may lead the FDA to deny 
approval. 
Those who claim that RTT laws are embedded in the right to die disregard the fact that, 
unlike the right to die situation, the consequences of access to experimental treatment in a 
RTT context has direct negative implications for RCTs and general public health 
interests. 
4.5. Patient-HCP communication  
RTT laws require patients to give informed consent, principally based on HCPs’ 
description of best and worst outcomes of using the experimental medical product. An 
assumption of these laws is that patients and HCPs have reasonable access to information 
about risks and benefits of taking an experimental medical product. This assumption and 
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the idea that patients can provide informed and voluntary consent under RTT laws has 
been strongly criticised.  
There is normally scant information available about the safety of medical products that 
have completed Phase 1, and clinical data about RCT is often unavailable to HCPs and 
patients (31). Therefore, HCPs who are asked to take informed consent may not be able 
to give patients meaningful information about the risks and benefits associated to the 
experimental medical product. This is a serious problem given that, as discussed 
previously, experimental medical products are likely to worsen the patient’s (medical, 
psychosocial and financial) condition.  
Critics have focused not only on the quantity and accuracy of the information available to 
terminally ill patients, but also on its comprehensiveness, or quality (32). Some critics 
have expressed concerns that RTT laws (and also EA) may limit the scope of HCPs-
patient interaction, and consequently patient decision making, placing too much 
emphasis on intensive forms of treatments, at the expense of other important clinical 
options such as palliative and hospice care. Palliative care focuses on improving quality 
of life, it can increase life span, it can be provided concurrently with treatments, and is 
more effective when administered early in the course of the illness (for example, the  
American Society of Clinical Oncology recommends early prescription of palliative care 
(33)). Clinical options that may improve the quality of life, and potentially life-spans 
such as palliative care may therefore be relevant to the needs and values of patients. Such 
options should be discussed with patients, and – also in a hypothetical context of RTT or 
EA – should be part of the consent process.  However, discussions about palliative care 
do not appear to be common in the USA context. In recent studies, 80% of Americans 
reported not to know what palliative care is, and both patients and providers often viewed 
palliative care as a sign of ‘giving up’(26).   
This is linked to other important ethical aspects of informed consent: the voluntary nature 
of request, and the absence of coercion and undue influence. In the USA (but also in 
other countries) there are strong social norms and expectations of maintaining a ‘fighting 
spirit’, keeping a positive attitude, or regaining power and control in the face of serious 
chronic or terminal conditions. These norms and expectations can have a negative impact 
on patients’ understanding, management and experience of illness (34). In the context of 
end of life care, HCPs can feel pressure to describe prognosis and benefits of 
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experimental treatments over-optimistically (or simply to avoid mentioning other options 
such as palliative care). At the same time terminally ill patients, and their families, can 
feel pressure to pursue intensive treatments ‘hoping to get better’, but instead potentially 
compromising the quality and length of their lives (35).  
This problem is also linked to the ethical concern of therapeutic misconception i.e. 
terminally ill patients – and more broadly any participant to medical research – may 
overestimate the benefit that experimental medical products can grant them. For example, 
some patients seeking RTT may believe that by having access to experimental medical 
products before their approval they may accelerate the completion of the RCT, helping 
not only themselves, but also other patients with similar conditions as well as future 
generations.  
End of life care should be a bidirectional process between patient and HCPs characterised 
by the communication of relevant information in a way that can help informing patients 
decisions i.e. flexible to the needs of the patients (36).  This implies that the information 
provided should be comprehensive, covering more options than the ‘intensive treatment 
focused’ EA or RTT ones, and include for example palliative care.  
In the case of patients and HCPs deciding to access experimental medical products, 
consent should cover an adequate disclosure of risks and benefits associated with the 
product – or lack of information thereof. This should include considering the financial 
aspects such as the purchase of the experimental product and payment for the 
management of medical condition associated with the use of the product. The discussion 
of risks should also include, if appropriate, the loss of hospice care due to use of 
experimental treatments. Finally, patients should be informed that access to experimental 
medical products outside RCT may compromise the development of the treatment for 
larger numbers of patients in the future. 
The EA programme has some measures in place to create conditions for informed and 
voluntary consent, therefore ultimately safeguarding individual autonomy more than 
RTT laws. For example the FDA receives updates after each phase of the clinical trial, 
and has information most HCPs do not (37). Moreover, the IRB is tasked with verifying 
that the consent form is accurate and that consent is voluntary (29, 30). Some critics have 
also suggested that in both EA and RTT contexts, psychiatrists or other ‘health coaches’ 
should be involved with assisting patients and HCPs to enhance communication skills 
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and decision making in important areas such as discussing prognosis and clinical 
pathways (17, 26).    
There is a form of ‘historical irony’ in RTT laws. Arguably RTT laws represent the 
current stage of a process of reframing – in an opposite vein – the conditions of patient 
consent to treatment and to participation in medical research. This reframing is counter to 
the concern – addressed by the development of informed consent – of protecting 
individuals from harm and risks associated to medical research and practice.  Informed 
consent was a reaction to the scientific abuses conducted particularly during the Second 
World War and some medical research in the post-war period on human subjects, who 
were not aware of the procedures they were undertaking.  It entails that HCPs and/or 
researchers have to take reasonable care to ensure that the patient is aware of material 
risk involved in the recommended treatment or participation to research (38). Within the 
RTT laws framework, the ‘protection’ of individual autonomy ‘stretches back’ to the idea 
of participating to early stages medical research when benefits, safety, and risks are 
unknown.       
5. Discussion 
RTT laws are specific to the American normative system, and would need to be 
significantly modified in order to export them to a different country. Nevertheless, 
something ethically relevant –and still ‘universal’ – might be learned from them, and 
from the consequent debate.  
There is an aspect in the RTT laws that may be certainly considered morally plausible, 
i.e. they place emphasis on the question of whether and how terminally ill patients should 
have timely access to experimental medical products. This aspect has to be taken into 
account when we morally weigh their content. The diverse international efforts to make 
medical products available before the completion of RCT appear to corroborate the 
relevance of this aspect.  Yet, our review has shown that there are other aspects of the 
RTT laws that pose some problems to their moral plausibility.  
To begin with, the rights they confer are formal, and not substantial. Not only because 
the procedure to obtain access to Phase1- medical products could be difficult, but also 
because the cost of the potential product is usually charged to the patient. This creates an 
unfair situation and economic inequalities, since only those who are affluent enough can 
have the substantial right to access these potential treatments.  
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Moreover, there is the issue of the lack of information about the side-effects of medical 
products which have passed Phase 1, which clashes with the RTT laws’ requirement that 
the requesting patient (or designated guardian) should give informed consent.  
We have also argued that there is a contradiction in RTT laws: they trust (or rely on) 
medical research to the extent that even its experimental products are worth trying as 
they may be beneficial – but at the same time do not trust the process and regulations 
medical research adopts to test and develop such products.  
Finally, we need to consider the relevant conflict between the potential interest of the 
terminally ill patient, and the public interest related to RCTs. To access an experimental 
medical product before the conclusion of a RCT could delay or derail its approval. This 
could harm present and future patients who may benefit from the RCT. 
Addressing all these problems is very challenging and requires a multifaceted strategy. 
Below we will suggest a multi-pronged strategy which blends ethical tools (already 
discussed within the bioethical community) aimed at improving the communication 
between HCPs and terminally ill patient, and some considerations to address the boarder 
social challenges that surround the RTT debate.  
5.1 Ethical tools 
 
‘Trusted’ Consent. As discussed previously, a truly informed consent to access an 
experimental medical product which has passed Phase 1 can be difficult to achieve, as it 
is too early to know the possible benefits and side effects of the product.  Different 
models of consent have been proposed in both clinical and research settings to overcome 
the problem of lack of information. This includes for example the context of research 
biobanks, in which the information provided to the givers – especially information 
concerning the secondary use of their samples – cannot be complete. The main idea 
proposed is a model of consent based on the concept of ‘trust’ (39-42) whereby consent 
is envisaged as a process, a bidirectional consultation between HCPs/researchers and 
patient/participants that goes beyond providing information (as per the traditional form of 
informed consent), but that is aimed at communicating values (i.e. the values of the 
HCPs/researchers and their instructions) and enabling choices. Such model is more 
realistic in contexts where it is not possible to access or there is not all the ‘relevant’ 
information required for a fully informed consent. This model is in line with the idea of 
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promoting an ethics of uncertainty (43), based on reciprocity between 
patients/participants and HCPs/researchers, and on co-producing decision making 
tailored to the patient/participant. Such model of consent based on trust may be both 
more achievable and suitable (than ‘informed’ consent) in the context of access to 
investigational products for terminally ill patients. However, we have seen that there may 
be other clinically viable options available to terminally ill patients besides access to 
experimental treatments. Therefore, something that precedes (and may or may not lead 
to) the trusted consent process may be needed to ensure that the communication between 
HCPs and terminally ill promotes decisions centred on the needs of the patients. 
 
Ethical Counselling. The second tool regards the possibility to introduce an ethical 
counselling service to improve end of life care and decision making. This tool could be 
available to the patient and to the HCP before the decision to request access to 
investigational medical products. The ethical counselling framework developed in 
Europe by Boniolo et al (44) is particularly suitable to this scope as it aims to improve 
decision making by helping both patients and HCPs to navigate complex clinical and 
ethical options, and by supporting choices that promotes patient autonomy i.e. decisions 
that are informed and in line with patients’ personal philosophies.  The term personal 
philosophy refers to the: “wide set of more or less deep, coherent and justified 
metaphysical, methodological, religious, political, esthetical, ethical, etc., beliefs, 
assumptions, principles, and values that an agent possesses and that characterises in a 
unique way how he/she approaches the world and life. […] (T)he ‘conceptual and value-
laden window’ from which any individual starts reflecting in order to make judgments, to 
make choices, and to act”, (44:p. xiii). Such ethical counselling approach would help 
terminally ill patients and HCPs to evaluate the information and options available and 
consider the implications of different choices. This would often include balancing the 
risks and benefits at individual (safety, costs, quality of life) and societal level (impact on 
RCT, public health), thus addressing most key concerns expressed by both sides of the 
RTT debate.  
Most aspects of the conflicts between individual and public interest, between individual 
autonomy and regulation of clinical research that can arise in the context of end of life 
care and RTT cannot be solved a priori, but require to be addressed on a case-by-case 
basis. Patients have different cultural backgrounds and needs; clinical options are also 
diverse, and can vary depending on the patient condition, priorities, clinical and other 
AC
CE
PT
ED
 M
AN
US
CR
IPT
18 
 
contextual factors. There is also another important observation to make. The fact that the 
harm caused by experimental treatments assessed through RTT can often exceed the 
potential benefit (see section 4.3), challenges the very existence of a ‘conflict’ between 
individual and public interest.  
In the absence of a substantial individual interest, the ‘individual/public’ conflict 
disappears, and what remains is the potential public interest in continuing a clinical trial. 
The RTT issues are underpinned by a strong libertarian view of individual autonomy 
whereby individuals are construed as self-sufficient, self-directed ‘atomic’ agents, 
capable of making independent decisions when informed. However, individuals are 
immersed in a complex network of relations and interdependencies. Applied to the 
context of medicine this means that illnesses are inextricable blends of biomedical 
information (sometimes incomplete), filtered through individual (the personal 
philosophy) and relational aspects (what has been called the lifeworld) (45).  
There are other ways to conceptualise autonomy that better approximate to this 
complexity, and that are conducive to promote choices aligned to the values and desired 
outcomes of the individual patient. There is an obvious need for a conceptualisation of 
autonomy that considers both internal factors (e.g. levels of understanding of medical 
information that is a disposal), and external factors (e.g. cultural social influences, 
income, vulnerability, emotional needs) that may influence patient understanding of 
information and decision making.  
This ethical counselling framework just outlined is in line with both the relational view 
of autonomy which recognised that individuals are immersed in a network of relations 
and interdependencies (41);  and with research conducted on patient-HCPs 
communication in end of life care, e.g. truth disclosure in oncology (46, 47). It offers 
some safety measure to protect patients from paternalistic medicine, therapeutic 
misconception, and to empower both vulnerable and more assertive patients. This is 
because:  i) it is patient-centred and aims to improve decision making by placing 
emphasis on the communication of the relevant information in a way that is tailored and 
responsive to patients’ personal philosophies and needs, and can inform the decision of 
the patient accordingly; ii) it takes into account possible cultural variations in relation to 
how to convey information, when, and how much; and iii) it is aimed at both patients and 
HCPs.  
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5.2 Points to consider  
We recognise – together with some critics of RTT laws – that the social challenges 
touched by these laws extend beyond the HCP-patient interaction. Hence, we present 
below three other points that deserve to be discussed. 
Stakeholder Engagement. The needs of terminally ill patients should not be 
underestimated. However, rather than bypassing the scientific and regulatory authority of 
the FDA, as the RTT laws do, it is important to identify and engage the stakeholders of 
medical research (e.g. patient advocates, producers, HCPs, health regulators and 
authorities, ethical counsellors, and bioethicists). That is, before implementing a RTT 
regulation (at whatever level it could be) it seems necessary to realise a good deliberative 
process (48-50) among all the stakeholders. This could provide a legitimate (by the 
deliberation itself) draft of the bill to be submitted to the legislative authority. In such a 
way the needs of all the stakeholders would be considered and the legislator could arrive 
at regulation that could satisfy all the parts involved (51).  
Information and education campaigns. There are many challenges with designing 
genuine (as opposed to tokenistic) stakeholder engagement (52).  A useful step would be 
to improve media information and education campaigns about the complex field of 
clinical trials (53), the tenuous nature of the development of medical products and the 
negative impact that unregulated access can have on individual patients (e.g. some 
patients have shorter and more miserable lives as a result of trying experimental medical 
products) and on public health. This will contribute to filling the ‘gap’ between experts 
and the public (7, 54, 55), having also a positive impact on the HCP-terminally ill patient 
clinical encounter.  
Cost considerations. RTT or similar programmes should not damage the capacity of a 
research team and/or clinical service to deliver other key ethical imperatives, e.g. offering 
equitable clinical care, or conducting medical research. Therefore, we press that any 
stakeholder engagement and communication endeavours should promote to changes in 
RTT, EA or any other programme with similar aims, that do not increase economic 
unfairness and inequality. 
As shown (see section 4.2), the RTT laws, as they are now, can increase inequalities.  
On the one hand, there is the company’s request to be paid for the medical product it is 
developing, and for which it has invested money and resources. Moreover, RCTs have 
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finite resources and a terminally ill patient request may shift research teams’ time and 
resources from conducting their RCT towards monitoring individual terminally ill 
patients who are not part of the RCT (and managing potential complications they may 
develop).   
On the other hand, there are patients who can afford the cost and those who cannot. In 
theory, it is unfair to both deny the potential treatment to patients who cannot afford the 
cost, and to deny those who can afford the cost the possibility to access the 
investigational medical product.  
A compromise should be found to properly substantiate the RTT or any similar 
programme. One possibility could be to establish a charity (or leverage already existing 
charities) to offer financial support to terminally ill patients who are not affluent and 
could receive benefit from the investigational medical product under RCT (this idea is 
similar to the private foundation established in Utah, see section 4.2).   
There is also the possibility that those who request access to the experimental medical 
product and are affluent could pay the cost of the product, alongside with a fee given to 
an institution which will use that money to support less economically affluent terminally 
ill patients. This fee could be justified not only on the basis of reducing inequalities of 
access i.e. on the ethical principle of justice, but also on the principle of reciprocity. 
Patients requesting access to experimental medical products should in fact to consider 
those who have been enrolled in the Phase 1. The fee could represent a ‘reward’ (which 
is available to other requesting patients) for what the participants to the clinical trial have 
given to the requesting patient: the possibility to use a Phase 1 approved treatment. This 
is a typical solidarity open ring: I take advantage of the solidarity of the volunteers 
enrolled in Phase 1, and someone else takes advantage of the fee that I pay over the cost 
of the potential treatment.    
6. Conclusions 
There is prevalence in the literature of arguments against RTT laws. This is at odds with 
the popularity of these laws and reflects a communication gap between the so-called 
experts, who oppose the laws, and the public.   
In this paper we have assessed the ethical plausibility of these laws. We have taken a 
moderate approach – in line with some of the literature – based on recognising that RTT 
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laws have contributed to raising awareness about the need to improve end of life care, but 
that they do not provide effective means to achieve this aim. This is largely because they 
tend to reduce the complexity of end of life care and the needs of terminally ill patients to 
issues of access to experimental medical products (and they also propose to do so in an 
ineffective way). However, whilst such issues might be relevant to some terminally ill 
patients, and in certain circumstances, there are other equally important aspects – related 
to the safety and choices of terminally ill patients, and to the rights and perspectives of 
other stakeholders – which are dangerously overlooked by these laws.  
On a conceptual level, we have identified a sort of contradiction in RTT laws. They trust 
(or rely on) medical research to the extent that even its early stage experimental products 
are ‘worth trying’ as they may be beneficial, but at the same time they do not trust the 
process used by medical research to test and develop such products. This is revealing of 
what we have referred to as a form of ‘historical irony’ whereby RTT laws represent the 
current stage of a process of reframing – in an opposite vein – the conditions of patient 
consent to treatment and to participation in medical research.   
On a more practical level, we have suggested a multi-pronged strategy based on a set of 
complementary ethical tools and considerations which might help to address most of the 
concerns raised by both sides of the RTT laws, respecting the interest and needs of the 
main stakeholders.      
Acknowledgments  
This paper was funded by the European School of Oncology. 
Conflict of interest 
The authors declare no conflict of interest  
Vitae 
Daniele Carrieri is a Research Fellow at Egenis, The Centre for the Study of Life 
Sciences, and at the Wellcome Centre for Cultures and Environments of Health, both 
based at the University of Exeter.  
Fedro Alessandro Peccatori is Scientific Director at the European School of Oncology 
and Director of the Fertility and Procreation Unit at the European Institute of Oncology, 
Milan, Italy. 
AC
EP
T
D M
AN
US
CR
IPT
22 
 
Giovanni Boniolo has the chair of Philosophy of Science and Medical Humanities at the 
Medical School of the University of Ferrara: http://docente.unife.it/giovanni.boniolo 
 
Bibliography  
1. Bernick E. Book Reviews: The Right to Try by Darcy Olsen. Engage. 2016;17(1):82-9. 
2. Rubin MJ, Matthews KR. The Impact of Right to Try Laws on Medical Access in the United States. 
The Baker Instutute Policy Report 2016;66. 
3. Rubin R. Experts critical of America's right-to-try drug laws. Lancet (London, England). 
2015;386(10001):1325-6. 
4. Leonard EW. Right to experimental treatment: FDA new drug approval, constitutional rights, 
and the public's health. The Journal of Law, Medicine & Ethics. 2009;37(2):269-79. 
5. Food & Drug Administration. Individual Patient Expanded Access Applications: Form FDA 3926. 
2016. 
6. Servick K. ‘Right to Try’laws bypass FDA for last-ditch treatments. Science. 
2014;344(6190):1329-. 
7. Dresser R. "Right to Try" Laws: The Gap between Experts and Advocates. The Hastings Center 
report. 2015;45(3):9-10. 
8. Miller JE, Ross JS, Moch KI, Caplan AL. Characterizing expanded access and compassionate use 
programs for experimental drugs. BMC research notes. 2017;10(1):350. 
9. Holbein ME, Berglund JP, Weatherwax K, Gerber DE, Adamo JE. Access to Investigational Drugs: 
FDA Expanded Access Programs or "Right-to-Try" Legislation? Clinical and translational science. 
2015;8(5):526-32. 
10. Ciani O, Buyse M, Drummond M, Rasi G, Saad ED, Taylor RS. Time to review the role of surrogate 
end points in health policy: state of the art and the way forward. Value in Health. 
2017;20(3):487-95. 
11. World Health Organization. Ethical considerations for use of unregistered interventions for 
Ebola virus disease (EVD). 2014. 
12. Wellcome Trust UK. Ebola Treatment Trials to Be Fast-Tracked in West Africa.  
13. Meyerson D. Medical Negligence Determinations, the "Right to Try," and Expanded Access to 
Innovative Treatments. Journal of bioethical inquiry. 2017. 
14. Lieu CH, Sorkin A, Messersmith WA. Right to try? Journal of clinical oncology : official journal of 
the American Society of Clinical Oncology. 2015;33(13):1518. 
15. Kirchoff MC, Pierson JF. Considerations for Use of Investigational Drugs in Public Health 
Emergencies. Therapeutic innovation & regulatory science. 2017;51(2):146-52. 
16. Cooper CJ, Khan Mirzaei M, Nilsson AS. Adapting Drug Approval Pathways for Bacteriophage-
Based Therapeutics. Frontiers in microbiology. 2016;7:1209. 
17. Piel J. Informed Consent in Right-To-Try Cases. The journal of the American Academy of 
Psychiatry and the Law. 2016;44(3):290-6. 
18. Caplan A. Medical Ethicist Arthur Caplan Explains Why He Opposes 'Right-to-Try' Laws. Oncology 
(Williston Park, NY). 2016;30(1):8. 
19. Kase NM. Do Right to Try Laws Undermine the FDA'S Authority? An Examination of the 
Consequences of Unlimited Access to Unapproved Drugs. The Journal of legal medicine. 
2015;36(3-4):420-41. 
20. Cohen-Kurzrock BA, Cohen PR, Kurzrock R. Health policy: The right to try is embodied in the 
right to die. Nature reviews Clinical oncology. 2016;13(7):399-400. 
21. Goldwater Institute. Right to Try Model Legislation. 2014. 
22. Zettler PJ, Greely HT. The strange allure of state "right-to-try" laws. JAMA internal medicine. 
2014;174(12):1885-6. 
AC
CE
PT
E
 M
AN
US
CR
IPT
23 
 
23. Knoepfler PS. From bench to FDA to bedside: US regulatory trends for new stem cell therapies. 
Advanced drug delivery reviews. 2015;82-83:192-6. 
24. Shapiro RS. Reconciling States’ “Right to Try” Legislation and FDA’s Expanded Access Program. 
Therapeutic innovation & regulatory science. 2017;51(2):153-6. 
25. Yang YT, Chen B, Bennett C. "Right-to-Try" Legislation: Progress or Peril? Journal of clinical 
oncology : official journal of the American Society of Clinical Oncology. 2015;33(24):2597-9. 
26. Hoerger M. Right-to-try laws and individual patient "compassionate use" of experimental 
oncology medications: A call for improved provider-patient communication. Death studies. 
2016;40(2):113-20. 
27. Hart JT. The inverse care law. The Lancet. 1971;297(7696):405-12. 
28. Hay M, Thomas DW, Craighead JL, Economides C, Rosenthal J. Clinical development success 
rates for investigational drugs. Nature biotechnology. 2014;32(1):40-51. 
29. Caplan AL, Bateman-House A. Should patients in need be given access to experimental drugs? 
Expert opinion on pharmacotherapy. 2015;16(9):1275-9. 
30. Bateman-House A, Kimberly L, Redman B, Dubler N, Caplan A. Right-to-try laws: hope, hype, and 
unintended consequences. Annals of internal medicine. 2015;163(10):796-7. 
31. Darrow  JJ, Avorn  J, Kesselheim  AS. New FDA Breakthrough-Drug Category — Implications for 
Patients. New England Journal of Medicine. 2014;370(13):1252-8. 
32. Jacob JA. Questions of Safety and Fairness Raised as Right-to-Try Movement Gains Steam. Jama. 
2015;314(8):758-60. 
33. Smith TJ, Temin S, Alesi ER, Abernethy AP, Balboni TA, Basch EM, et al. American Society of 
Clinical Oncology Provisional Clinical Opinion: The Integration of Palliative Care Into Standard 
Oncology Care. Journal of Clinical Oncology. 2012;30(8):880-7. 
34. Frank AW. The Wounded Storyteller: Body, illness, and Ethics: University of Chicago Press; 2013. 
35. Gawande A. Being mortal: medicine and what matters in the end: Metropolitan Books; 2014. 
36. Annoni M, Schiavone G, Chiapperino L, Boniolo G. Constructing the Medical Humanities gaze. 
Critical reviews in oncology/hematology. 2012;84:S5-S10. 
37. Friedman LM, Furberg C, DeMets DL, Reboussin DM, Granger CB. Fundamentals of clinical trials: 
Springer; 2010. 
38. National Commission for the Protection of Human Subjects of Biomedical and  Behavioral 
Research. The Belmont Report: Ethical Principles and Guidelines for the Protection of Human 
Subjects of Research-the National Commission for the Protection of Human Subjects of 
Biomedical and Behavioral Research: US Government Printing Office; 1978. 
39. Sanchini V, Bonizzi G, Disalvatore D, Monturano M, Pece S, Viale G, et al. A Trust‐Based Pact in 
Research Biobanks. From Theory to Practice. Bioethics. 2016;30(4):260-71. 
40. Boniolo G, Di Fiore PP, Pece S. Trusted consent and research biobanks: towards a ‘new 
alliance’between researchers and donors. Bioethics. 2012;26(2):93-100. 
41. Prainsack B, Buyx A. Solidarity in Biomedicine and Beyond: Cambridge University Press; 2017. 
42. O'neill O. Autonomy and trust in bioethics: Cambridge University Press; 2002. 
43. Newson AJ, Leonard SJ, Hall A, Gaff CL. Known unknowns: building an ethics of uncertainty into 
genomic medicine. BMC medical genomics. 2016;9(1):57. 
44. Boniolo G, Sanchini V. Ethical Counselling and Medical Decision-Making in the Era of 
Personalised Medicine. Boniolo G, Sanchini V, editors: Springer International Publishing; 2016. 
45. Mishler EG. Research Interviewing: Context and Narrative: Harvard University Press; 1986. 
46. Surbone A. Truthfulness of More Optimistic vs Less Optimistic Messages for Patients With 
Advanced Cancer. JAMA oncology. 2015;1(5):687-8. 
47. Surbone A. Telling the truth to patients with cancer: what is the truth? The Lancet Oncology. 
2006;7(11):944-50. 
48. Boniolo G. The Art of Deliberating: Democracy, Deliberation and the Life Sciences Between 
History and Theory: Springer; 2012. 
AC
CE
PT
ED
 M
AN
US
CR
IPT
24 
 
49. Boniolo G, Schiavone G. Deliberation and Democracy A2 - Wright, James D.  International 
Encyclopedia of the Social & Behavioral Sciences (Second Edition). Oxford: Elsevier; 2015. p. 61-
7. 
50. Schiavone G, De Anna G, Mameli M, Rebba V, Boniolo G. Libertarian paternalism and health care 
policy: a deliberative proposal. Medicine, Health Care and Philosophy. 2014;17(1):103-13. 
51. Carrieri D, Bewshea C, Walker G, Ahmad T, Bowen W, Hall A, et al. Ethical issues and best 
practice in clinically based genomic research: Exeter Stakeholders Meeting Report. Journal of 
Medical Ethics. 2016;42(11):695-7. 
52. Gibson A, Britten N, Lynch J. Theoretical directions for an emancipatory concept of patient and 
public involvement. Health:. 2012;16(5):531-47. 
53. Sanchini V, Reni M, Calori G, Riva E, Reichlin M. Informed consent as an ethical requirement in 
clinical trials: an old, but still unresolved issue. An observational study to evaluate patient's 
informed consent comprehension. Journal of medical ethics. 2014;40(4):269-75. 
54. Begg CB, Kim K, Neaton JD. "Right to Try" laws. Clinical trials (London, England). 2014;11(5):519-
20. 
55. DeTora LM. What is safety?: Miracles, benefit-risk assessments, and the "right to try". 
International journal of clinical practice. 2017;71(7). 
 
 
AC
CE
PT
ED
 M
AN
US
CR
IPT
